Retinal Surgery

A team of investigators at the Agency for Science, Technology and Research in Singapore have developed a bio-functional thermogel, a type of synthetic polymer, to prevent retinal scarring caused by failed retinal detachment repair surgery.

Foundation Fighting Blindness is a driving force in advancing retinal gene therapies into clinical trials.

The 40th annual Scientific Meeting of the American Society of Retina Specialists is scheduled for July 13-16, 2022, in New York.

A study by Orbis International found that children with myopia experienced significantly higher levels of depression and anxiety than their peers without vision impairment.

Though the speed of traditional guillotine cutters has increased significantly in recent years, there are certain limitations. With the advent of hypersonic vitrectomy, Sunir J. Garg, MD, FACS, explains how retinal surgeons can remove the vitreous gel with more efficiency.

Results from our recent poll regarding Retina World Congress 2022 attendance indicate that while many retina specialists will attend the Congress, the majority will not be in Fort Lauderdale, Florida.

Investigators from the Karolinska Institutet and St. Erik Eye Hospital, Stockholm, Sweden, reported that they have developed a prognostic test, referred to as serUM, that they believe is a strong predictor of metastasis of uveal melanoma.

A poll for retina specialists regarding their attendance at the 2022 Retina World Congress in Fort Lauderdale, Florida. This poll is now closed.

The trial marks the first-ever in vivo delivery of an experimental CRISPR gene editing medicine to a pediatric patient, with the company on track to complete dosing of the pediatric mid-dose cohort in the first half of 2022.

According to researchers at the University of California, Irvine, base editing may provide long-lasting retinal protection and prevent vision deterioration in patients with inherited retinal degeneration, specifically in Leber congenital amaurosis patients.

The company’s announcement marks first clinical trial in humans of Ocugen’s modifier gene therapy platform.

Lower dose performs as effectively as a higher dose when treating ROP.

In the face of the COVID-19 pandemic, the procedure required adjustments.

Investigators observe survival rate with orbital retinoblastoma improves substantially due to a combination approach that includes intensive sequential treatment comprised of chemotherapy, enucleation, and external beam radiation therapy.

Ultrasonic retinal prosthesis has been achieved by a research group at UCLA. It is a step towards a non-invasive retinal prosthesis that works without invasive eye surgery.

This new surgical technique offers precision down to the micron level, which is more precise than a surgeon can achieve by themselves.

Dr. Aleksandra Rachitskaya discusses how the treatment landscape for Inherited Retinal Diseases has changed and her hope for the future.

While there is currently no cure for blindness, an artificial vision system has undergone its first successful implantation, bringing with it the potential to restore partial vision to people who have lost their sight.

The latest invention from Mark S. Humayun, MD, PhD, brings hope to sufferers of age-related macular degeneration, a common type of blindness.

Recent literature review reveals dearth of data, highlights need for more research.

Under terms of the agreement, ImprimisRx to assume full responsibility for US sales and marketing activities for Dexycu.

Jay Duker, MD, discusses EYP-1901, EyePoint Pharmaceuticals’ sustained-release anti-VEGF drug for the treatment of wet AMD.

Options facilitate increased durability for patients with retinal degeneration.

Dr. Timothy G. Murray discusses the 5-year follow-up data from a large, consecutive case series of combined anterior and posterior segment surgery and the benefits of a single procedure for the recovery of vision and decreased risk.

Leo Kim, MD, PhD, discusses his presentation at ASRS 2021, entitled "Rho-kinase inhibition on an in vitro patient-derived model of proliferative vitreoretinopathy."

Proposal hints at the use of generative adversarial network (GAN) for applications in macular surgery.

Pilot study shows promise of teaching surgeons with technology.

Programming includes 16 EURETINA sessions; 22 symposia; 44 instructional courses; 85 hours of content, and more than 300 speakers.

With orphan drug and fast track status, Neurotech plans to seek FDA approval for its NT-501 Implant platform late next year.